Quarterly report pursuant to Section 13 or 15(d)

Business Combinations (Details Textual)

v2.4.0.6
Business Combinations (Details Textual) (USD $)
In Millions, unless otherwise specified
1 Months Ended 6 Months Ended 7 Months Ended
Jan. 31, 2012
Jan. 31, 2011
Medications
Company
Licensee
Jun. 30, 2012
Employee
Jul. 31, 2012
Jan. 24, 2011
Business Combinations (Textual) [Abstract]          
Number of FDA-approved medications   6      
Number of licensees   3      
Minimum number of companies supported by CyDex for drug development efforts   40      
Cash paid to CyDex shareholders         $ 32.0
Contingent Value Rights fair value         19.2
Discounted to present value using a discount rate         21.60%
Fair Value of Contingent liability     13.7    
Paid to CyDex shareholders 4.3   0.3 3.5  
Additional amount required to pay 6.0        
Percentage of related revenue     20.00%    
Amount exceeds to get related revenue for CyDex share holders     15.0    
Percentage of related revenue additional     10.00%    
Aggregate CyDex-related revenue     35.0    
Percentage of related revenue, current year     0.20    
Amount excess of CyDex-related revenue     15    
Number of employees required     5    
Investments for acquiring employees     $ 1.5